Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From Business - Malaysian Talks

Hong Kong students issue government deadline over demands

Jun 20, 2019

HONG KONG — A Hong Kong student group demanded Wednesday that the city completely scrap a politically charged extradition bill and agree to investigate police tactics against protesters before a Thursday deadline or face further street demonstrations. Meanwhile, the Civil Human Rights Front, which organized massive marches on the past two Sundays, called for another protest on July 1, the anniversary of Hong Kong's handover from British to Chinese rule in 1997. Since last Sunday's march on the government headquarters by an estimated 2 million people, the number of protesters in the area has dropped to just a few dozen....

Hong Kong protesters slam leader's apology, demand she quit

Jun 20, 2019

HONG KONG — Hong Kong pro-democracy lawmakers and activists rejected a new apology Tuesday by the city's leader over a highly unpopular extradition bill, demanding that she quit and that the legislation be scrapped completely. Lam's plea for "another chance" drew a chorus of criticism, though members of pro-Beijing political parties and her Cabinet, the Executive Council, expressed their support. Some activists said if the government does not meet those and other demands by a 5 p.m. Thursday deadline, they plan a mass "resistance movement." That would follow a peaceful but rousing march Sunday by some 2 million people worried...

The Latest: HK protesters mass outside city leader's office

Jun 20, 2019

HONG KONG — The Latest on protests in Hong Kong against an extradition bill (all times local): 5:40 p.m. Protesters in Hong Kong have gathered outside the office of the city's leader, demanding that she resign for her handling of an unpopular extradition bill. The mostly young demonstrators blocked a street Monday near the city's waterfront as they stood outside the office of Chief Executive Carrie Lam, chanting calls for her to give up the proposed legislation. Lam has apologized for the crisis and suspended work on the bill, which would allow suspects to face trial in mainland Chinese courts....

The Latest: Hong Kong protest activists reject apology

Jun 20, 2019

HONG KONG — The Latest on protests in Hong Kong against an extradition bill (all times local): 11:15 p.m. Pro-democracy activists helping to drive mass protests in Hong Kong over a proposed extradition law have rejected an apology issued by the city's leader. Leaders of the Civil Human Rights Front said Sunday that they estimated almost 2 million people had marched to demand Chief Executive Carrie Lam scrap the legislation and resign. Police have not issued an estimate of the crowd size. Many remained gathered outside the city government's headquarters after the march, apparently planning to spend the night there....

Hong Kong marchers gather as protester's death mourned

Jun 20, 2019

HONG KONG — Hong Kong residents were gathering Sunday for another massive protest over an unpopular extradition bill that has highlighted the territory's apprehension about relations with mainland China, a week after the crisis brought as many as 1 million into the streets. A steady stream of mourners were stopping by a makeshift memorial, meanwhile, to lay flowers and pray for a man who fell to his death Saturday after hanging a protest banner. The man slipped from the grasp of rescuers after clinging for a time to scaffolding outside a shopping mall. He missed a big cushion set up...